Pascal Prigent (Genfit)
October 1, 2020 06:31 AM EDTUpdated 07:11 AM
R&D

Gen­fit prunes near­ly half its work­force af­ter NASH ex­it — but CEO promis­es a fu­ture in PBC, di­ag­nos­tics

Amber Tong

Two months af­ter Gen­fit’s lead drug, elafi­bra­nor, failed a close­ly-watched Phase III show­down, the French biotech threw in the tow­el on NASH al­to­geth­er. An­oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times